Aarti Drugs Limited

NSEI:AARTIDRUGS Stock Report

Market Cap: ₹43.3b

Aarti Drugs Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Prakash Patil

Chief executive officer

₹27.8m

Total compensation

CEO salary percentage41.5%
CEO tenure39.9yrs
CEO ownership9.6%
Management average tenure11.3yrs
Board average tenure8.3yrs

Recent management updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04
Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01
Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30
Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17
Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22
These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28
We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19
Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17
Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04
Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17
Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Feb 17
What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

Feb 04
Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Jan 22
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07
Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23
If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08
Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08
How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

CEO Compensation Analysis

How has Prakash Patil's remuneration changed compared to Aarti Drugs's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹2b

Jun 30 2024n/an/a

₹2b

Mar 31 2024₹28m₹12m

₹2b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹28m₹11m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹31m₹10m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹2b

Mar 31 2021₹35m₹8m

₹3b

Dec 31 2020n/an/a

₹3b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹2b

Mar 31 2020₹19m₹7m

₹1b

Dec 31 2019n/an/a

₹1b

Sep 30 2019n/an/a

₹1b

Jun 30 2019n/an/a

₹888m

Mar 31 2019₹15m₹7m

₹898m

Dec 31 2018n/an/a

₹863m

Sep 30 2018n/an/a

₹887m

Jun 30 2018n/an/a

₹943m

Mar 31 2018₹14m₹7m

₹823m

Compensation vs Market: Prakash's total compensation ($USD327.05K) is about average for companies of similar size in the Indian market ($USD268.38K).

Compensation vs Earnings: Prakash's compensation has been consistent with company performance over the past year.


CEO

Prakash Patil (77 yo)

39.9yrs

Tenure

₹27,848,000

Compensation

Mr. Prakash Moreshwar Patil has been the Chairman of the Board of Aarti Drugs Limited since April 2014. Mr. Patil has been the Managing Director of Aarti Drugs Limited since June 1, 2007 and serves as its...


Leadership Team

NamePositionTenureCompensationOwnership
Prakash Patil
Chairmanno data₹27.85m9.59%
₹ 4.2b
Harshit Savla
Joint MD & Executive Director21.7yrs₹25.54m4.71%
₹ 2.0b
Adhish Patil
CFO & COO12.4yrs₹11.44m1.23%
₹ 533.5m
Rushikesh Deole
Company Secretary & Compliance Officer5.7yrs₹1.17mno data
Harit Shah
Whole-Time Directorno data₹25.54m4.43%
₹ 1.9b
Uday Patil
Whole-Time Director24.2yrs₹3.35m0.055%
₹ 23.7m
Rashesh Gogri
MD & Executive Director10.3yrs₹25.54m4.61%
₹ 2.0b
Dhanaji Kakade
Vice President of Technicalno datano datano data
Vishwa Savla
Managing Director of the Pinnacle Life Science Private Limitedless than a yearno data1.02%
₹ 442.8m

11.3yrs

Average Tenure

61yo

Average Age

Experienced Management: AARTIDRUGS's management team is seasoned and experienced (11.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Prakash Patil
Chairman39.9yrs₹27.85m9.59%
₹ 4.2b
Harshit Savla
Joint MD & Executive Director37.9yrs₹25.54m4.71%
₹ 2.0b
Harit Shah
Whole-Time Director29.3yrs₹25.54m4.43%
₹ 1.9b
Uday Patil
Whole-Time Director24.2yrs₹3.35m0.055%
₹ 23.7m
Rashesh Gogri
MD & Executive Director12.3yrs₹25.54m4.61%
₹ 2.0b
Chandrakant Gogri
Chairman Emeritus12.3yrs₹43.00k1.86%
₹ 805.6m
Neha Gada
Independent Director2.6yrs₹155.00kno data
Sandeep Joshi
Additional Independent Directorless than a yearno datano data
Narendra Salvi
Non-Executive Director4.3yrs₹100.00kno data
Ankit Paleja
Independent Director3.2yrs₹215.00kno data
Bhaskar Thorat
Independent Director2.6yrs₹155.00kno data
Hasmukh Dedhia
Additional Independent Directorless than a yearno datano data

8.3yrs

Average Tenure

61yo

Average Age

Experienced Board: AARTIDRUGS's board of directors are considered experienced (8.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:51
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aarti Drugs Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rashmi Sancheti ShettyCGS International
Rashmi Sancheti ShettyDolat Capital Market Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research